共 381 条
[1]
Liu W(2022)Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019 Aging (Albany NY) 14 3175-3190
[2]
Liu J(2019)Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet 396 1204-1222
[3]
Song Y(2019)NCCN guidelines insights: B-cell lymphomas, Version 3.2019 J Natl Compr Canc Netw 17 650-661
[4]
Wang X(2022)NCCN Guidelines® insights: Hodgkin lymphoma, version 2.2022 J Natl Compr Canc Netw 20 322-334
[5]
Mi L(2021)Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma Cochrane Database Syst Rev 9 Cd013365-2195
[6]
Cai C(2019)CAR T cell therapy: a new era for cancer treatment (Review) Oncol Rep 42 2183-4678
[7]
Zhao D(2020)Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies Blood Adv 4 4669-33
[8]
Wang L(2020)Anti-CD19 CAR T-cell therapy for B-Cell Non-Hodgkin lymphoma Transfus Med Rev 34 29-55
[9]
Ma J(2019)Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management Blood Rev 34 45-971
[10]
Zhu J(2018)Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia Cancer Discov 8 958-374